Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2033 ARTÍCULOS , VIENDO DEL 466 AL 480

Multiple Metabolites Derived from Mushrooms and Their Beneficial Effect on Alzheimer's Diseases

Tong Z, Chu G, Wan C, Wang Q, Yang J, Meng Z, Du L, Yang J, Ma H.

Nutrients. 2023 Jun 15;15(12):2758. doi: 10.3390/nu15122758.

Tipping points in neurodegeneration

Simons M, Levin J, Dichgans M.

Neuron. 2023 Oct 4;111(19):2954-2968. doi: 10.1016/j.neuron.2023.05.031. Epub 2023 Jun 28.

Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future

Zhang Y, Chen H, Li R, Sterling K, Song W.

Signal Transduct Target Ther. 2023 Jun 30;8(1):248. doi: 10.1038/s41392-023-01484-7.

As a Potential Therapeutic Target, C1q Induces Synapse Loss Via Inflammasome-activating Apoptotic and Mitochondria Impairment Mechanisms in Alzheimer's Disease

Guan PP, Ge TQ, Wang P.

J Neuroimmune Pharmacol. 2023 Sep;18(3):267-284. doi: 10.1007/s11481-023-10076-9. Epub 2023 Jun 29.

Gauging innovation and health impact from biomedical research: survey results and interviews with recipients of EU-funding in the fields of Alzheimer's disease, breast cancer and prostate cancer

Pistollato F, Campia I, Daskalopoulos EP, Bernasconi C, Desaintes C, Di Virgilio S, Kyriakopoulou C, Whelan M, Deceuninck P.

Health Res Policy Syst. 2023 Jun 29;21(1):66. doi: 10.1186/s12961-023-00981-z.

Amyloid precursor protein and its interacting proteins in neurodevelopment

Chau DD, Ng LL, Zhai Y, Lau KF.

Biochem Soc Trans. 2023 Aug 31;51(4):1647-1659. doi: 10.1042/BST20221527.

Cognitive rehabilitation for people with mild to moderate dementia

Kudlicka A, Martyr A, Bahar-Fuchs A, Sabates J, Woods B, Clare L.

Cochrane Database Syst Rev. 2023 Jun 29;6(6):CD013388. doi: 10.1002/14651858.CD013388.pub2.

The shared role of cholesterol in neuronal and peripheral inflammation

Hansen SB, Wang H.

Pharmacol Ther. 2023 Sep;249:108486. doi: 10.1016/j.pharmthera.2023.108486. Epub 2023 Jun 29.

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

Yu HJ, Dickson SP, Wang PN, Chiu MJ, Huang CC, Chang CC, Liu H, Hendrix SB, Dodart JC, Verma A, Wang CY, Cummings J.

EBioMedicine. 2023 Aug;94:104665. doi: 10.1016/j.ebiom.2023.104665. Epub 2023 Jun 29.

Targeting dynamin-related protein-1 as a potential therapeutic approach for mitochondrial dysfunction in Alzheimer's disease

Bhatti JS, Kaur S, Mishra J, Dibbanti H, Singh A, Reddy AP, Bhatti GK, Reddy PH.

Biochim Biophys Acta Mol Basis Dis. 2023 Oct;1869(7):166798. doi: 10.1016/j.bbadis.2023.166798. Epub 2023 Jun 29.

Failure of current Alzheimer's disease hypotheses

Wood PL.

Aging (Albany NY). 2023 Jul 1;15(13):5959-5960. doi: 10.18632/aging.204880. Epub 2023 Jul 1.

The Novel Role of Mitochondrial Citrate Synthase and Citrate in the Pathophysiology of Alzheimer's Disease

Chhimpa N, Singh N, Puri N, Kayath HP.

J Alzheimers Dis. 2023;94(s1):S453-S472. doi: 10.3233/JAD-220514.

Association between insulin and Nrf2 signalling pathway in Alzheimer's disease: A molecular landscape

Rahman SO, Khan T, Iqubal A, Agarwal S, Akhtar M, Parvez S, Shah ZA, Najmi AK.

Life Sci. 2023 Sep 1;328:121899. doi: 10.1016/j.lfs.2023.121899. Epub 2023 Jun 30.

m (6)A methylation in cellular senescence of age-associated diseases

Gao P, Yao F, Pang J, Yin K, Zhu X.

Acta Biochim Biophys Sin (Shanghai). 2023 Jul 3;55(8):1168-1183. doi: 10.3724/abbs.2023107.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias